Clinical Trial Update: Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 1/2 safety and efficacy study of BMS-908662 alone or in combination with Cetuximab in KRAS or BRAF …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• BMS-908662
• ERBITUX (cetuximab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Colorectal Cancer | Phase 1, Phase 2 | Status: COMPLETED